Procrit Sales Data
| Rank 63 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Procrit U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 63 ( 12) |
$241,535 | -10.09% | 261 | -10.00% |
| Q3 2013 | 51 ( 4) |
$268,630 | 5.08% | 290 | 2.47% |
| Q2 2013 | 55 (6) |
$255,636 | 6.00% | 283 | 4.81% |
| Q1 2013 | 61 (3) |
$241,175 | -2.24% | 270 | -3.23% |
| Q4 2012 | 58 (1) |
$246,708 | -6.07% | 279 | -4.45% |
| Q3 2012 | 57 (10) |
$262,659 | -10.20% | 292 | -7.59% |
| Q2 2012 | 47 (11) |
$292,501 | 10.72% | 316 | 7.12% |
| Q1 2012 | 58 (3) |
$264,190 | -2.13% | 295 | -4.22% |
| Q4 2011 | 55 (2) |
$269,937 | 3.58% | 308 | 3.01% |
| Q3 2011 | 53 (12) |
$260,610 | -21.61% | 299 | -21.32% |
| Q2 2011 | 41 (7) |
$332,466 | 7.04% | 380 | 5.56% |
| Q1 2011 | 48 | $310,606 | n/a | 360 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
